{
  "documentMetadata": {
    "title": "Endocarditis, Prosthetic Valve, Empiric Therapy",
    "lastUpdated": "2025-01-27",
    "sourceFile": "Endocarditis, Prosthetic Valve, Empiric Therapy.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Empiric therapy, pending culture results, for patient with prosthetic valve and signs and symptoms of endocarditis.",
        "Initial presentation may be subtle, such as unexplained heart failure. Fever may not be prominent.",
        "Use of 18F-FDG-PET/CT allowed recategorization of 76% of prosthetic valve endocarditis initially classified as \"possible\" by Duke criteria to \"definite\" infectious endocarditis (Clin Infect Dis. 2020;70: 583)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Early (< 2 months post op)"
        },
        {
          "type": "list",
          "items": [
            "Staph. aureus",
            "Staph. epidermidis",
            "Rarely: Enterobacteriaceae, diphtheroids, fungi"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Late (> 2 months post-op):"
        },
        {
          "type": "list",
          "items": [
            "Staph. aureus",
            "Staph. epidermidis",
            "Viridans streptococci",
            "Enterococci"
          ]
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "regimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q8-12h"
          },
          {
            "drug": "Cefepime",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q8h",
            "connector": "+"
          }
        ],
        "notes": "to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL) (See Comments)"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "regimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "as above"
          },
          {
            "drug": "Gentamicin",
            "dose": "3 mg/kg",
            "route": "IV",
            "frequency": "once daily",
            "connector": "+"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Once a microbiologic diagnosis has been made, definitive therapy should be pathogen directed."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "There is no evidence-based, preferred regimen for empirical therapy of suspected endocarditis. The regimen listed as primary therapy provides adequate initial coverage for the most likely pathogens: S. aureus and S. epidermidis, including methicillin-resistant strains; Enterobacteriaceae (a consideration in early-onset infection); streptococci; enterococci; and HACEK organisms. Gentamicin is not listed as a preferred agent because even low doses for short durations can be toxic, particularly if another potentially nephrotoxic agent such as vancomycin is co-administered. Rifampin, although recommended for staphylococcal prosthetic valve endocarditis, is not listed as an empirical agent because it should be administered after 3-5 days of effective antibiotic therapy to minimize the potential for emergence of resistance due to high bacterial burdens.",
        "Early surgical consultation is advised especially if etiology is Staph. aureus, evidence of heart failure, presence of diabetes and/or renal failure, or concern for valve ring abscess (JAMA 297:1354, 2007; Clin Infect Dis 44:364, 2007).",
        "Early valve surgery not associated with improved 1-year survival in S. aureus prosthetic valve endocarditis Clin Infect Dis 60:741, 2015.",
        "References for surgical therapy of prosthetic valve endocarditis: Eur J Cardiothorac Surg 38:528, 2010; New Engl J Med 368:1425, 2013; JAMA 312:1323, 2014."
      ]
    }
  ]
}